Toxoplasmosis Testing Market to Reach US$576.7M

Market Size & Forecast

The Toxoplasmosis Testing Market was valued at approximately US$354 million in 2019 and is anticipated to reach US$577 million by 2027, growing at a CAGR of 6.4% between 2022 and 2029.

Serological tests remain dominant, projected to climb from US$ $260 million in 2019 to US$ $427 million by 2027 at a CAGR of 6.5%, while diagnostic labs lead the end-user segment with nearly 50% market share.

Introduction & Definition

Toxoplasmosis testing encompasses diagnostic methods—serological assays, PCR-based molecular tests, and imaging for congenital cases—targeting Toxoplasma gondii, a common parasite. Testing is critical for pregnant women, immunocompromised patients, and in food safety screening, helping detect acute infections or past exposure via IgG/IgM serology, though PCR delivers early diagnosis and higher sensitivity.

To buy the report, click on https://www.datamintelligence.com/buy-now-page?report=toxoplasmosis-testing-market

Segmentation Analysis

By Test Type:

Serological tests dominate globally, offering high throughputs and cost-efficiency.
PCR & molecular diagnostics are the fastest growing (~8.1% CAGR through 2027), offering precise detection even in early or ocular toxoplasmosis.
Imaging (ultrasound/MRI) and invasive techniques (amniocentesis, biopsy) are important for prenatal and cerebral toxo cases.

By End User:

Hospitals lead due to infrastructure and patient inflow.
Diagnostic laboratories are scaling cost-effective PCR and multiplex assays.
Clinics and specialized maternity centers are increasingly adopting point-of-care kits.

Geographical Insights

North America accounted for over 35% of the market in 2019 and is expected to grow due to high pork consumption, diagnostic awareness, and advanced healthcare.
Europe shows higher seroprevalence (20–77%), prompting strong demand for routine testing, especially in Germany and France.
Asia-Pacific is expanding with investments in diagnostic infrastructure and increasing foodborne risk, led by China, India, and Japan.
Japan reports around 10.3% antibody prevalence among pregnant women, especially those aged 35+, with growing prenatal screening programs.

Latest News & Industry Trends (US & Japan)

United States:

Rapid adoption of multiplex PCR panels and automated immunoassays has improved turnaround times, with real-time PCR now providing results within hours.
Point-of-care Rapid tests are being piloted, especially in prenatal and primary care settings, to enable early intervention.

Japan:

Integration of automated PCR platforms in perinatal clinics supports early detection of congenital toxoplasmosis.
Increased government focus on food safety testing, due to widespread consumption of undercooked or free-range meats, is driving demand for lab testing.
To get the free sample, click on https://www.datamintelligence.com/download-sample/toxoplasmosis-testing-market

Competitive Landscape

Key players in the market include

ACON Laboratories offers EIA kits for prenatal IgG screening
Abbott
BioMérieux
Bio-Rad Laboratories
DiaSorin
Thermo Fisher Scientific
Biokit
Genemedi
Gold Standard Diagnostics

These companies are focusing on strategies like new product launches, acquisitions, automated multiplex assay development, and expansion into the point-of-care segment.

Impact Analysis

Improved public health outcomes: Early detection in pregnancy significantly reduces congenital toxoplasmosis risks.
Clinical efficiency: Rapid molecular diagnostics cut result times dramatically, increasing access in underserved regions.
Economic efficiency: Automated and multiplex testing lowers per-test costs, enabling wider routine screening.
Global equity: Point-of-care and telemedicine-based testing improve access in low-resource settings.

Key Developments

Bio-Rad acquired Curiosity Diagnostics to enhance its molecular diagnostics portfolio.
Rapid multiplex PCR assays and automated testing platforms have been rolled out across North America and Europe.
Pilot programs in the US and Japan have launched rapid IgG/IgM point-of-care kits and bundled prenatal testing initiatives. About Us

DataM Intelligence is a global market intelligence firm dedicated to providing actionable insights and data-driven strategies. Our expert research teams serve a wide range of industries, including healthcare, biotechnology, technology, and chemicals, helping clients make well-informed decisions.